AnemiaNCT06318858
Daily and Weekly Iron Supplementation in Infants
A study testing Iron supplement in people with Anemia and Iron Status, run by Mahidol University at 1 site in Thailand.
Trial summary
This study aims to compare the efficacy of daily iron supplementation and weekly iron supplementation in infants aged 6-12 months on the prevalence of anemia, hemoglobin level, and serum ferritin levels. Read more about this study
- Who is it for?
- Ages 6 to 12 monthsHealthy volunteers can take part
- Conditions the study is for
- Anemia, Iron Status, Infants
- What is being tested?
- Iron supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 287 participants
- Where
- 1 siteThailand
- Study dates
- 15 Mar 2023to 14 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 12 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Apparently healthy infant, aged 6 months ± 2 weeks
- Having a birth weight between 2,500 and 4,000 grams
- Being born full term (37 to 41 weeks of age + 6 days)
- Having hemoglobin ≥ 10.5 g/dL
- Being planned to breastfeed with complementary food and/or complementary foods with formula milk
Who cannot join
- Infants with chronic illnesses or thalassemia clinical signs such as anemia, enlarged liver, or spleen (if parental history suggests the child is at risk of developing a thalassemia disease that may not show clinical symptoms)
- Previously or currently taking an iron supplement
Trial locations and contacts
1 site in 1 country.
Thailand1 site
Samphran District Hospital
Sam Phran, Changwat Nakhon Pathom, 73110
About this study
Official title: Efficacy of Daily and Weekly Iron Supplementation on Anemia Prevalence in Thai Infants Aged 6-12 Months
This study aims to compare the efficacy of daily iron supplementation and weekly iron supplementation in infants aged 6-12 months on the prevalence of anemia, hemoglobin level, and serum ferritin levels. Infants will be enrolled at 6 months and will be randomly assigned to receive either daily or weekly iron supplementation for the first 3 months and will be followed by weekly iron supplementation for another 3 months.
Read the detailed description
This study aims to compare the efficacy of daily iron supplementation and weekly iron supplementation in infants aged 6-12 months on the prevalence of anemia, hemoglobin level, and serum ferritin levels. Normal birth weight and term infants will be enrolled at 6 months based on the inclusion criteria. Eligible participants will be assessed at baseline, including anthropometry, dietary intake, and biochemistry (hemoglobin, iron status, vitamin A status, and inflammation). Participants will then be randomly assigned to receive either daily or weekly iron supplementation for the first 3 months. Participants will be followed up at 9 months for the same assessments and will receive weekly iron supplementation for another 3 months. Participants will be followed up at 12 months and the same assessments will be performed. After that, participants will go back to the routine health care service, weekly iron supplementation.
- Conditions
- Anemia, Iron Status, Infants, Iron
- Being tested
- Iron supplement
- Keywords
- Anemia, Iron status, Infants, Iron supplementation
- Medical subject headings
- Anemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Iron supplementDietary supplement
Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
| Study group | Role | What they receive |
|---|---|---|
| Group 1 daily iron supplementation | Experimental | 12.5 mg daily iron syrup supplementation from 6-9 months old, followed by 12.5 mg weekly iron syrup supplementation from 9-12 months old.
Infants aged 6-9 months will receive two iron syrup bottles. One bottle aims for ingestion every Monday of the week, and one bottle aims for ingestion on other days of the week.
At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week. Receives: Dietary Supplement: Iron supplement |
| Group 2 weekly iron supplementation | Other | 12.5 mg weekly iron syrup supplementation from 6-12 months old. Infants aged 6-9 months will receive an iron syrup bottle that aims for ingestion every Monday of the week and a placebo bottle that aims for ingestion on other days of the week.
At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week. Receives: Dietary Supplement: Iron supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anemia status
Hemoglobin concentration will be assessed and classified as anemia or non-anemia.
Measured: at aged 6, 9, and 12 months
Iron status
Serum ferritin will be assessed to reflect iron status
Measured: at aged 6, 9, and 12 months
Secondary outcomes (4)
Weight
Body weight will be assessed, and weight-for-age and weight-for-length Z scores will be generated
Measured: at aged 6, 9, and 12 months
Length
Length will be assessed, and length-for-age Z scores and weight-for-length will be generated
Measured: at aged 6, 9, and 12 months
Dietary intake
Dietary intake will be assessed using the 24-hr dietary recall for 3 days
Measured: at aged 6, 9, and 12 months
Head circumference (HC)
HC will be assessed, and head circumference-for-age Z scores will be generated
Measured: at aged 6, 9, and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2024
- Study start15 Mar 2023
- Primary completion25 Oct 2024
- Study completion14 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnemiaStudies of the same condition, open and under way.
- More trials run by Mahidol UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- group 1: daily iron syrup supplementation group 2: weekly iron syrup supplementation
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 287 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mahidol University
- Sponsor type
- University, hospital or other
- Collaborators
- Suranaree University of Technology
- Responsible party
- Sponsor
- Investigators
- Tippawan Pongcharoen, PhD, Principal investigator, Mahidol University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06318858
- Sponsor's protocol ID
- MU-CIRB 2022/313.1411
- Status last verified
- May 2026
- First submitted
- 13 Mar 2024
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Daily and Weekly Iron Supplementation on Anemia Prevalence in Thai Infants Aged 6-12 Months
- ClinicalTrials.gov ID
- NCT06318858
- Acronym / sponsor ID
- MU-CIRB 2022/313.1411
- Conditions
- Anemia, Iron Status, Infants, Iron
- Keywords
- Anemia, Iron status, Infants, Iron supplementation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 287 participants (actual)
- Lead sponsor
- Mahidol UniversityUniversity, hospital or other
- Collaborators
- Suranaree University of Technology
- Study start
- 15 Mar 2023 (actual)
- Primary completion
- 25 Oct 2024 (actual)
- Study completion
- 14 May 2025 (actual)
- First posted
- 19 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the efficacy of daily iron supplementation and weekly iron supplementation in infants aged 6-12 months on the prevalence of anemia, hemoglobin level, and serum ferritin levels. Infants will be enrolled at 6 months and will be randomly assigned to receive either daily or weekly iron supplementation for the first 3 months and will be followed by weekly iron supplementation for another 3 months.
Detailed description
This study aims to compare the efficacy of daily iron supplementation and weekly iron supplementation in infants aged 6-12 months on the prevalence of anemia, hemoglobin level, and serum ferritin levels. Normal birth weight and term infants will be enrolled at 6 months based on the inclusion criteria. Eligible participants will be assessed at baseline, including anthropometry, dietary intake, and biochemistry (hemoglobin, iron status, vitamin A status, and inflammation). Participants will then be randomly assigned to receive either daily or weekly iron supplementation for the first 3 months. Participants will be followed up at 9 months for the same assessments and will receive weekly iron supplementation for another 3 months. Participants will be followed up at 12 months and the same assessments will be performed. After that, participants will go back to the routine health care service, weekly iron supplementation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- group 1: daily iron syrup supplementation group 2: weekly iron syrup supplementation
| Arm | Type | Receives |
|---|---|---|
| Group 1 daily iron supplementation | Experimental | Dietary Supplement: Iron supplement12.5 mg daily iron syrup supplementation from 6-9 months old, followed by 12.5 mg weekly iron syrup supplementation from 9-12 months old. Infants aged 6-9 months will receive two iron syrup bottles. One bottle aims for ingestion every Monday of the week, and one bottle aims for ingestion on other days of the week. At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week. |
| Group 2 weekly iron supplementation | Other | Dietary Supplement: Iron supplement12.5 mg weekly iron syrup supplementation from 6-12 months old. Infants aged 6-9 months will receive an iron syrup bottle that aims for ingestion every Monday of the week and a placebo bottle that aims for ingestion on other days of the week. At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week. |
Who may qualify
- Ages
- 6 to 12 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Apparently healthy infant, aged 6 months ± 2 weeks
- Having a birth weight between 2,500 and 4,000 grams
- Being born full term (37 to 41 weeks of age + 6 days)
- Having hemoglobin ≥ 10.5 g/dL
- Being planned to breastfeed with complementary food and/or complementary foods with formula milk
Key exclusion criteria (2 listed)
- Infants with chronic illnesses or thalassemia clinical signs such as anemia, enlarged liver, or spleen (if parental history suggests the child is at risk of developing a thalassemia disease that may not show clinical symptoms)
- Previously or currently taking an iron supplement
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Iron supplementGroup 1: 12.5 mg daily iron syrup supplementation from 6-9 months old | Dietary supplement | Group 1 daily iron supplementation, Group 2 weekly iron supplementation |
Primary outcome
Anemia status
Time frame: at aged 6, 9, and 12 months
Hemoglobin concentration will be assessed and classified as anemia or non-anemia.
Iron status
Time frame: at aged 6, 9, and 12 months
Serum ferritin will be assessed to reflect iron status
4 secondary outcomes
Weight
Time frame: at aged 6, 9, and 12 months
Length
Time frame: at aged 6, 9, and 12 months
Dietary intake
Time frame: at aged 6, 9, and 12 months
Head circumference (HC)
Time frame: at aged 6, 9, and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Anemia
RecruitingPhase 1/2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Aplastic Anemia, Refractory
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tippawan Pongcharoen, PhD principal investigator
Mahidol University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Iron supplement in people with Anemia and Iron Status, run by Mahidol University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anemia status (time frame: at aged 6, 9, and 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.